Macrogenics (MGNX) Revenue (2012 - 2026)

Macrogenics (MGNX) has reported Revenue for 15 consecutive years, with $20.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 57.48% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $157.1 million (down 10.08% YoY), while the FY2025 annual figure was $149.5 million, changed 0.31% from the prior year.
• Revenue slipped to $20.8 million in Q1 2026 per MGNX's latest filing, from $41.2 million in the prior quarter.
• Across five years, Revenue topped out at $110.7 million in Q3 2024 and bottomed at $9.1 million in Q1 2024.
• Historically, Revenue has averaged $32.4 million across 5 years, with a median of $22.2 million in 2025.
• Annual changes were most pronounced in 2023 — Revenue slumped 85.33% — and 2024, when it surged 964.81%.
• Macrogenics' Revenue stood at $73.1 million in 2022, then plunged by 85.33% to $10.7 million in 2023, then soared by 273.13% to $40.0 million in 2024, then advanced by 3.07% to $41.2 million in 2025, then slumped by 49.61% to $20.8 million in 2026.
• Business Quant data shows MGNX's Revenue at $20.8 million in Q1 2026, $41.2 million in Q4 2025, and $72.8 million in Q3 2025.